AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02712034 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MAT
Description: Patients will receive treatment consisting of a recovery plan, appropriate pharmacology, routine urine screens, and regularly scheduled behavioral interventions, such as monthly group counseling sessions or sessions with a recovery coach. Appropriate pharmacology may include methadone; naltrexone; buprenorphine; and in the case of overdose, naloxone; and other medications and combinations of medications as part of the patient's standard clinical care.
Study NCT00801008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and relaxation intervention
Description: Comparison of an exercise and relaxation intervention to a wait-list control condition
Study NCT00801008 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Exercise and relaxation intervention
Description: Comparison of an exercise and relaxation intervention to a wait-list control condition
Study NCT01492075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCRA (Intermittent injection)
Description: Intermittent injection of LA intraabdominally
Study NCT01492075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCRA (Intermittent injection)
Description: Intermittent injection of LA intraabdominally
Study NCT04483960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: The dose of intravenous remdesivir is 200 mg on day 1 followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first. Remdesivir will be administered as an intravenous infusion via a central or peripheral venous catheter over a 30-120 minute period, as per local practice.
Study NCT01625221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Anal Sphincter
Description: The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
Study NCT01263834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
Study NCT01263834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
Study NCT01647490 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent Cardiac Pacemaker Implantation
Study NCT01647490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Permanent Cardiac Pacemaker Implantation
Study NCT01355393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu peptide vaccine
Description: Given ID
Study NCT01355393 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HER-2/neu peptide vaccine
Description: Given ID
Study NCT01355393 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sargramostim
Description: Given ID
Study NCT01355393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given ID
Study NCT01355393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rintatolimod
Description: Given ID
Study NCT04349345 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: sperm count
Description: total progressive sperm motile count
Study NCT00932373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab-MCC-DM1
Description: Intravenous escalating dose
Study NCT01835873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's
Study NCT02410512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
Description: MOXR0916 will be administered intravenously.
Study NCT03243539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Protective Ventilation
Description: Neuro lung protective ventilation for patients with acute brain injury is designed to target a normal partial pressure of arterial carbon dioxide and decrease initial tidal volumes toward a target 6 ml/kg predicted body weight PBW (range 6 to 8 ml/kg PBW)
Study NCT05236946 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic radiosurgery/whole brain radiotherapy
Description: SRS/ WBRT for asymptomatic brain metastases depending on the number of brain metastases
Study NCT05236946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor
Description: TKI
Study NCT05236946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tyrosine kinase inhibitor
Description: TKI
Study NCT03907995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The form of treatment will involve 6 group sessions every two weeks about an hour each. Sessions consist of teaching a different coping technique in each session to help cope with disaster or other events.
Study NCT04088019 — intervention group
Intervention type: DRUG
Intervention: Fixed drug combination (FDC) of ATT and Oral steroid
Description: In the first two week, patients receive FDC of ATT only. Oral steroid start to be given in week three.~The ATT regiment is continued for up to 6 months or more, in accordance with WHO guidelines. In the first two months the antibiotic combination given consisted of isoniazid (INH), rifampicin, pyrazinamide, and ethambutol. The next four months or continuation phases, the ATT given is rifampicin and isoniazid.~The following dosage and administration of oral steroids will be given to patients, according to guidelines from the American Journal of Ophthalmologists (Douglas A. Jabs et al, 2000):~Initial dose: 1mg/kg/day, with maximum adult oral dose 60-80 mg/kg and maintenance dose less than or equal to 10 mg/day. The tapering schedule: Over 40 mg/day, decrease by 10 mg/day every 1-2 weeks, 40-20 mg/day, decrease by 5 mg/day every 1-2 weeks, 20-10 mg/day, decrease by 2.5 mg/day every 1-2 weeks, 10-0 mg/day, decrease by 1 to 2.5 mg/day every 1-4 weeks.
Study NCT03923933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Description: Chlorthalidone
Study NCT03923933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bumetanide
Description: Bumetanide
Study NCT03923933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Bumetanide
Study NCT04582474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dengue module and rapid diagnostic tests
Description: Digital platform providing clinical decision support for Dengue, Dengue rapid diagnostic tests and training will be deployed at study sites for Dengue screening, diagnosis, case management as well as reporting to surveillance system following local guidelines
Study NCT03942133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided short-axis placement of catheter at the entrance of the adductor canal
Description: Ultrasound probe is placed at the entrance of the adductor canal in short axis ，insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the entrance of the canal
Study NCT03942133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided long-axis placement of catheter at the middle of the adductor canal
Description: Ultrasound probe is placed at the middle of the adductor canal in long axis with the caphelad end of the probe aligned with the entrance of the canal. insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the middle of the canal
Study NCT02794376 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Study NCT02794376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Study NCT02794376 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting Period
Study NCT04983381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia education video
Description: The multimedia education video was a 30 minutes information-based patient education program and contained information about pelvic anatomy and how to practice vaginal examination. The same gynecologist (M.S.) (male) who 15 years of experience explained details of vaginal examination, who told about vaginal examination in this video to the study participants, also did the gynecologic examination. The gynecologic examination which contained pelvic ultrasound scan and vaginal examination lasted approximately 20 minutes practice.
Study NCT04523896 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Real time High-Dose-Rate prostate brachytherapy in combination with stereotactic prostate radiotherapy
Description: - Brachytherapy: Real time HDR prostate brachytherapy using a MRI-trans-rectal ultrasound image fusion protocol: single fraction of 15 Gy.~Planning software: Oncentra prostate (Nucletron)~- External beam radiotherapy: Stereotactic ablative radiation therapy (SABR): 5 session in 5 consecutive days, 5 Gy per fraction to the prostate.~Intra-fraction gold seeds monitoring using Auto beam Hold solution (Varian) Planning software: Eclipse (Varian).
Study NCT03167307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: Omega-3 fatty acids in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
Study NCT03167307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: medium chain triglycerides in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
Study NCT02454101 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cord milking
Description: milking of the cord 5 times toward the neonate
Study NCT02454101 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: delayed cord clamping
Description: delay clamping of the cord for 120 seconds
Study NCT04073238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level Red-light Therapy
Description: In addition to wearing single vision spectacle lens with power for correcting distance refraction, low-level red-light therapy is performed twice per school day at home with an interval of at least 4 hours, each treatment lasting 3 minutes.
Study NCT01835873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HES 130/0.42
Description: Balanced colloid solution
Study NCT03818282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin-bound)
Description: Paclitaxel for injection (albumin-bound) 260 mg/m2, i.v., d1; AUC = 5 for carboplatin injection, i.v., infusion completed on day 1-3; Repeated every 3-4 weeks for 6-8 cycles.
Study NCT01206998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel
Description: Subjects will receive daily vaginal progesterone gel provided by Columbia laboratories (1.125g progesterone gel containing 90mg (8%) progesterone)
Study NCT01206998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal gel
Description: Subjects will receive daily placebo vaginal gel, made of an identical bioadhesive delivery system as the active drug
Study NCT02275065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir
Description: Bictegravir tablet(s) administered orally once daily
Study NCT02275065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match bictegravir administered orally once daily
Study NCT02495051 — intervention group
Intervention type: PROCEDURE
Intervention: esophageal biopsies
Study NCT01025440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)~Duration:
Study NCT03326505 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical cord derived Mesenchymal Stem Cells
Description: Allogenic umbilical cord derived stem cells which are to be injected intrathecally as a treatment option for consenting MS patients
Study NCT04124835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swiss Ball
Description: Top narrow (DeLee Plan -5 to -1 or Hodge Plan 1-3) Retroversion, lateralization and pelvic circumference exercises with abducted hips and external rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and external rotation.~Lower Narrow (DeLee Plan +1 to +5 or Hodge Plan 3-4) Pelvic anteversion, tilt, and circumference exercises with abducted hips and internal rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and internal rotation.
Study NCT04124835 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Grup
Description: Habitual Care of the Service.
Study NCT01662817 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intervention
Description: PCP receives one day training in depression screening guidelines and uses guidelines for six months
Study NCT03326505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised physical therapy
Description: A combined physical therapy program of Balance, strengthening and endurance exercises
Study NCT03451734 — intervention group
Intervention type: DRUG
Intervention: antipsychotic medications
Description: olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups
Study NCT03451734 — intervention group
Intervention type: DRUG
Intervention: adjunctive group
Description: antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups.
Study NCT03451734 — intervention group
Intervention type: DRUG
Intervention: metformin and lifestyle intervention
Description: different dose metformin combines lifestyle intervention
Study NCT03450018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC-0111
Description: Oral SLC-0111
Study NCT03450018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injection
Description: 1000 mg/m\^2 IV
Study NCT03158883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 \[±2\] days).
Study NCT03158883 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SAR)
Description: SAR: the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated.
Study NCT03314766 — intervention group
Intervention type: DEVICE
Intervention: IC-8 IOL
Description: Patients previously implanted with an IC-8 IOL contralaterally or bilaterally will be evaluated for their long-term visual functions and overall satisfaction at least 12 months post-implantation
Study NCT00455663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training
Description: Environmental supports for all independent living skills
Study NCT00455663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharm-Cognitive Adaptation Training
Description: Environmental supports for medication and appointment adherence
Study NCT01662817 — intervention group
Intervention type: BEHAVIORAL
Intervention: Control
Description: PCP manages depression in the usual way for six months
Study NCT05411666 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Saline solution maintenance of the CVC
Description: Saline solution maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B\|Braun, according to local standard procedures.
Study NCT05411666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No maintenance of the CVC
Description: No maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B\|Braun. Just visual inspection to local site of CVC insertion.
Study NCT02459912 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Unilateral Nerve-Sparing Cryoablation of the Prostate
Description: The side of the prostate affected by cancer will be treated with nerve-sparing cryoablation in two freeze-thaw cycles under transrectal ultrasound guidance. The unaffected side of the prostate will not be treated.
Study NCT00455663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Medication follow-up and limited case management provided by local community mental health authority
Study NCT00903383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX3305 low dose
Description: A low dose of LX3305; daily oral intake for 12 weeks
Study NCT00903383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX3305 mid dose
Description: A mid dose of LX3305; daily oral intake for 12 weeks
Study NCT02459912 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Precise Cryoablation System with IceRod Needles
Description: Galil Medical Precise Cryoablation System with IceRod Needles will be used for performing Unilateral Nerve-Sparing Cryoablation
Study NCT04024345 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Barratt Simplified Measure of Social Status (BSMSS)
Description: Questionnaire that evaluates cultural identity, educational level and occupation of the subject and the subject's parents and spouse (if any)
Study NCT04024345 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Global Assessment of Functioning scale (GAF)
Description: Used to measure overall levels of functionality of an individual
Study NCT04024345 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: General Self-Efficacy Scale (GSES)
Description: Psychometric scale that is designed to assess optimistic self-beliefs to cope with a variety of difficult demands in life
Study NCT04024345 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Perceived Stress Scale (PSS)
Description: To assess the perceived stress
Study NCT04024345 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coping Orientation to Problems Experienced (Brief COPE),
Description: It evaluates the subject's coping style through investigation of problem-solving abilities and emotional fluctuation, as a response to stressful situations
Study NCT04024345 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multidimensional Scale of Perceived Social Support (MSPSS)
Description: to explore the subject's social support system
Study NCT00288366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone vs. aripiprazole
Description: ziprasidone vs. aripiprazole dosed according to package insert
Study NCT00288366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole vs. ziprasidone
Description: aripiprazole vs. ziprasidone dosed according to package insert
Study NCT00903383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX3305 high dose
Description: A high dose of LX3305; daily oral intake for 12 weeks
Study NCT00903383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo dosing with daily oral intake for 12 weeks
Study NCT04075071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teacher-Child Interaction Training - Universal
Description: Teacher-Child Interaction Training - Universal (TCIT-U) is an empirically-supported classroom-based intervention designed to strengthen teacher-child relationships, reduce and prevent child behavior problems, and promote social-emotional skills. TCIT-U is based in behavioral and attachment principles and was developed as a modification of Parent-Child Interaction Therapy (PCIT), an evidence-based treatment with well-established support for decreasing disruptive child behaviors and parental stress with children ages two to seven years old. In TCIT-U, teachers of children, preschool through second grade, are taught and coached in skills to manage challenging classroom behaviors and improve the quality of relationships. TCIT-U is delivered to teachers through group didactic training and live individualized coaching.
Study NCT02477332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QGE031
Study NCT02477332 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Study NCT02477332 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02993146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00109538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: 200 mg twice daily (BID, ie, approximately 12 hours apart with food), oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
Study NCT00109538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID, oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria